PADN for PH-HF
Pulmonary Hypertension due to Left Heart Disease (Group II)
ClinicalPatient enrollment ongoing in China
Key Facts
Indication
Pulmonary Hypertension due to Left Heart Disease (Group II)
Phase
Clinical
Status
Patient enrollment ongoing in China
Company
About Pulnovo Medical
A Chinese medtech leader developing catheter-based denervation therapies for pulmonary hypertension and heart failure.
View full company profile